# CEPR

> Centre d'étude des pathologies respiratoires


## Posts

- [Young Researcher Adeline Cezard Presents New Anti-Influenza Therapeutic Approaches at ARNS-MIE 2026](https://cepr-inserm.fr/2026/04/09/young-researcher-adeline-cezard-presents-new-anti-influenza-therapeutic-approaches-at-arns-mie-2026/): The Centre d’étude des pathologies respiratoires (INSERM U1100) (Tours) is pleased to highlight the presentation given by Adeline Cezard at the ARNS-MIE scientific meeting, held on April 1–2, 2026 at the Cité Internationale Universitaire de Paris. She presented innovative work exploring new perspectives for anti-influenza therapies based on a metabolite, offering promising insights for future research in the field. We warmly thank ARNS-MIE for the invitation and for organizing such a stimulating scientific event that fosters discussion and the dissemination of advances in infectious diseases. The ARNS-MIE (Agence nationale de recherches sur le sida et les maladies infectieuses émergentes) is
- [❓How can we better quantify the host response during sepsis?](https://cepr-inserm.fr/2026/04/07/%e2%9d%93how-can-we-better-quantify-the-host-response-during-sepsis/): 😊 Very proud to share our new article published in the prestigious The Lancet Respiratory Medicine journal! 🎓 In this work, we developed a parsimonious machine-learning tool to define and quantify immune dysregulation, supporting a more biologically informed approach to immunomodulation.This approach has the potential to improve prognostication, enhance the evaluation of treatment responses, and identify patients most likely to benefit from targeted immunomodulatory therapies. CEPR INSERM LabUniversité de ToursInserm Grand Ouesthashtag#immunomodulation hashtag#machine-learning hashtag#clinical data https://www.sciencedirect.com/science/article/pii/S2213260025004291  
- [journée scientifique du CEPR](https://cepr-inserm.fr/2026/04/03/journee-scientifique-du-cepr/): Cette journée scientifique du CEPR a été un véritable temps fort, de réflexions et de contributions inspirantes autour des thématiques qui animent notre laboratoire. Ces moments partagés ensemble, dans un cadre agréable, ont largement favorisé la convivialité, stimulé l’inspiration et créé une très belle énergie collective ! Un grand merci à tous et à toutes pour votre implication et votre ouverture, ainsi qu’aux intervenants et aux organisateurs pour la qualité de cette journée. Cette retraite illustre parfaitement que, malgré les aléas de la vie d’un laboratoire de recherche, il est toujours possible de créer des espaces de collaboration et de
- [Congratulations to Louna Pili for Her best presentation award at the Scientific Symposium of the SRLF in Paris!](https://cepr-inserm.fr/2026/03/31/congratulations-to-louna-pili-for-its-best-presentation-award-at-the-scientific-symposium-of-the-srlf-in-paris/): Congratulations to Louna Pili for winning the Best Oral Presentation Award at the Société de Réanimation de Langue Française (SRLF) scientific symposium in Paris. This award reflects the relevance of her research, the quality of her work, and her ability to present her ideas clearly to clinicians and fellow students. It was a great opportunity to share her findings and connect with experts in the field.
- [Professor Antoine Guillon receives the Eloi Collery Prize in recognition of his research achievements over the past five years.](https://cepr-inserm.fr/2026/01/16/professor-antoine-guillon-receives-the-eloi-collery-prize-in-recognition-of-his-research-achievements-over-the-past-five-years/): Professor Antoine Guillon Awarded the Eloi Collery Prize for His Research on Influenza ” On December 16, the French National Academy of Medicine awarded the Eloi Collery Prize to Professor Antoine Guillon, in recognition of his research achievements over the past five years. His work has notably led to the discovery of the antiviral effects of specific metabolites from the Krebs cycle, paving the way for novel therapeutic strategies against influenza. A clear objective: improving therapeutic responses to influenza Influenza viruses are among the most contagious pathogens, infecting more than one billion people worldwide each year. In France, seasonal influenza
- [Congratulations to Mike Pasteur for the successful defense of his thesis](https://cepr-inserm.fr/2025/12/19/congratulations-to-mike-pasteur-for-the-successful-defense-of-his-thesis/): Congratulations to Mike Pasteur for the successful defense of his thesis: “Biomimetic model of human nasal cavity for drug development”
- [Congratulations to Sandra Khau for her Thesis defense !](https://cepr-inserm.fr/2025/12/18/congratulations-to-sandra-khau-for-her-thesis-defense/): Congratulations to Sandra Khau for the successful defense of her thesis: “Inflammasome regulation during bacterial and fungal superinfection in cystic fibrosis“
- [Congratulations to Florian VEILLARD on obtaining his HDR](https://cepr-inserm.fr/2025/12/16/congratulations-to-florian-veillard-on-obtaining-his-hdr/): Congratulations to Florian, who brilliantly obtained his habilitation to direct research ! This is a remarkable accomplishment that reflects his  expertise in the field of proteases in inflammation and host-pathogen interactions
- [Christmas time 🎄](https://cepr-inserm.fr/2025/12/12/christmas-time-%f0%9f%8e%84/): Today was an opportunity to share a moment of conviviality to conclude a year rich in projects: the CEPR wishes everyone a wonderful holiday season.
- [Congratulations to Alexis David for the successful defense of his thesis](https://cepr-inserm.fr/2025/12/09/congratulations-to-alexis-david-for-the-successful-defense-of-his-thesis-inhibition-de-la-cathepsine-s-par-des-polysaccharides-dorigine-naturelle-ou-synthetique/)
- [Cytosolic receptors and signaling in antifungal immunity](https://cepr-inserm.fr/2025/12/05/cytosolic-receptors-and-signaling-in-antifungal-immunity/): 👍 Nice work from Sandra Khau and colleagues from CEPR INSERM Lab (Team “ Pathophysiology of lung infections”) in embojournal.org. They propose a didactic review summarizing the cytosolic receptors and the signaling pathways involved in antifungal innate immunity.
- [Congratulations to our PhD student Katia Montero-Diaz](https://cepr-inserm.fr/2025/12/04/congratulations-to-our-phd-student-katia-montero-diaz/): 👏 Congratulations to our PhD student Katia Montero-Diaz for her excellent presentation at the #SFMNano congress in Lyon!  👍 A great showcase of the progress taking place in our lab (Pharmacology of Inhaled Pharmaceuticals team) and within the RNAVAC consortium
- [Double recognition for CEPR in cystic fibrosis research!](https://cepr-inserm.fr/2025/10/28/double-recognition-for-cepr-in-cystic-fibrosis-research/): At the French Symposium for Young Researchers in Cystic Fibrosis #CFJC2025, Sandra Khau, a PhD student at CEPR, received the ‘My Thesis in 3 Minutes’ award! In addition, the Michel Chignard prize, awarded prior to the conference, went to Benoit Briard, a researcher at CEPR. Congratulations to him! On 4 February, nearly 150 participants gathered at the Imagine Institute to discuss scientific advances in cystic fibrosis. Post-doctoral researchers, engineers, medical interns and master’s students presented their work through oral presentations and poster sessions, making it a particularly dynamic day. https://www.youtube.com/watch?v=cOB4XQxUVDA
- [Biotechnocentre conference](https://cepr-inserm.fr/2025/10/20/biotechnocentre-symposium/): CEPR was well represented at the #Biotechnocentre conference! Congratulations to our PhD students, Baptiste Rigoux and Katia Montero-Diaz, for their posters, and to our team leaders @Nathalie Heuzé-Vourc’h and @Christophe Paget for their brilliant presentations. Special mention goes to Alexis David, a third-year PhD student who won the prize for best oral presentation!
- [congress of three SFBBM Thematic Groups](https://cepr-inserm.fr/2025/10/16/congress-of-three-sfbbm-thematic-groups/): Dear Colleagues, We are pleased to announce the official opening of registration and abstract submissions (posters and oral presentations) for the joint congress of three SFBBM Thematic Groups : Enzymes, Proteolysis & Metabolism at the Crossroads of Biochemistry📅 3–5 December 2025Paris – Auditorium Buffon, Université Paris Cité (13ᵗʰ district)🌐 Conference website: https://gts-sfbbm-2025.sciencesconf.org
- [The CEPR looks forward to seeing you at the Science Village in Tours!](https://cepr-inserm.fr/2025/10/10/the-cepr-looks-forward-to-seeing-you-at-the-science-village-in-tours/): Cells, microbes, enzymes, aerosols and much more: come and discover the research topics covered by the Centre for the Study of Respiratory Diseases at the Science Festival! See you at Tours Town Hall on 11 and 12 October 2025.
- [2025 ANNUAL MEETING PEPR Biotherapies and Bioproduction of Innovative Therapies](https://cepr-inserm.fr/2025/10/03/2025-annual-meeting-pepr-biotherapies-and-bioproduction-of-innovative-therapies/): Congratulations to our doctoral students, Enzo Vidy, Katia Montero-Diaz, and postdoctoral researcher Bhupinder Kaur, for their excellent presentations at the PEPR Biotherapies and Bioproduction of Innovative Therapies conference in Montpellier! A wonderful showcase of the advances being made at CEPR. #France2030 #PEPR #Biotherapies #Bioproduction
- [Brilliant presentation of Margaux’s PhD work](https://cepr-inserm.fr/2025/09/29/brilliant-presentation-of-margauxs-phd-work/): Brilliant presentation of Margaux’s PhD work at the 20th edition of the Microbes Congress, organized by the Société Française de Microbiologie! She had the opportunity to present part of my PhD work on post-influenza aspergillosis superinfections, and to exchange with an outstanding community of researchers, clinicians, and fellow students. 🦠🍄
- [Congratulations to Alexis DAVID for its best presentation award at the  annual SFBMEc Congress in Toulouse!](https://cepr-inserm.fr/2025/09/24/congratulations-to-alexis-david-for-its-best-presentation-award-at-the-annual-sfbmec-congress-in-toulouse/)
- [CEPR invites you to take part in a science escape game on 9 October 2025!](https://cepr-inserm.fr/2025/09/24/cepr-invites-you-to-take-part-in-a-science-escape-game-on-9-october-2025/): It’s Science Day at CEPR! CEPR invites you to take part in a science escape game on 9 October 2025! Come and discover the world of research and its mysteries in a real laboratory. Your mission: Investigate a mysterious disease and find a cure! Registration is required by telephone on 02 47 36 60 49 or by email at secretariat.cepr@univ-tours.fr ! See you on 9 October for 1-hour sessions between 10 a.m. and 5 p.m. at 10 Boulevard Tonnellé in Tours On the forecourt of the Faculty of Medicine
- [Lab Publication: Advancing Targeted Therapies for HER2-Positive Breast Cancer](https://cepr-inserm.fr/2025/09/09/lab-publication-advancing-targeted-therapies-for-her2-positive-breast-cancer/):  😊  Very proud to share our new article published in J. Med. Chem!🎓 We showed the interest of one of our new linker technologies allowing the production of high-performance loaded immunoconjugates which present improved plasma stability and internalization within cancer cells compared to the Gold Standard T-DXd.
- [Congratulations to Professor Guillaume DESOUBEAUX](https://cepr-inserm.fr/2025/09/02/congratulations-to-professor-guillaume-desoubeaux/): Guillaume was appointed president by the general assembly of the French Society of Medical Mycology (SFMM) for the next four years.
- [impact of biological barriers on inhaled antibodies](https://cepr-inserm.fr/2025/08/01/%f0%9f%98%8a-excited-to-share-our-latest-publication-in-european-journal-of-pharmaceutics-and-biopharmaceutics-on-the-impact-of-biological-barriers-on-inhaled-antibodies/): 😊 Excited to share our latest publication in European Journal of Pharmaceutics and Biopharmaceutics on the impact of biological barriers on inhaled antibodies! 👏 This work is the result of a highly productive, collaborative, and enjoyable partnership with CSL Behring. A special thank you to @ and the entire team for their great contributions! 👉 doi.org/10.1016/j.ejpb.2025.114817
- [ANR fundings 2025](https://cepr-inserm.fr/2025/07/11/anr-fundings-2025/): 😀 Great ANR-2025 results for the CEPR!! 👏 Congratulations to Christophe Paget and Nathalie Heuzé-Vourc’h for their participation in the ALS-IMMUNE (CE17) and PETREL (CE18) programs! 👏 Congratulations to Noémie Alphonse and Benoît Briard for obtaining their Young Researcher grants (ANR JCJC, CE15), Ti-LAB and AspSTAT5 respectively. This bodes well for exciting discoveries and a new dynamic for our teams!
- [Summer event ☀️](https://cepr-inserm.fr/2025/07/08/summer-event/): A relaxation day at the CEPR !!Bowling and billiards are on the agenda for this summer event ! A wonderful day to conclude a rich and dynamic academic year for our laboratory.
- [PhD Day - Centre-Val de Loire Region](https://cepr-inserm.fr/2025/06/30/phd-day-de-la-region-centre-val-de-loire/): 👏 Very proud of the CEPR INSERM Lab PhD students!! Oral presentation and posters for the Centre-Val de Loire Region PhD Day. 😀 Congratulations, you are flying the flag for your laboratory! University of Tours – Inserm  
- [Aerosolized Antibiotic Therapy in Mechanically Ventilated Patients](https://cepr-inserm.fr/2025/06/17/aerosolized-antibiotic-therapy-in-mechanically-ventilated-patients/): We are presenting a concise overview of the existing rationale and evidence and provide guidance for implementing inhaled antibiotics among ventilated critically ill patients, published in the American Journal of Respiratory and Critical Care Medicine.
- [CEPR Team 3 Featured on "Radio Campus Tours"](https://cepr-inserm.fr/2025/05/27/cepr-team-3-featured-on-radio-campus-tours/): The Team 3 (Virginie Hervé, Sandrine Le Guellec & Mike Pasteur) was recently on air during La Méridienne, the daily radio show on Radio Campus Tours 99.5 FM!  We had a very enjoyable time sharing our work with Melissa Wyckhuyse, as we discussed the different in vitro models developed in our lab for the advancement of new inhaled therapies. 👏 Many thanks to Melissa Wyckhuyse, Pierre DaSilva (Ph.D.), and Jean-Michel Escoffre, Ph.D., for organizing this inspiring edition of Les Méridiennes! 🎧 You can listen to the full episode of the show via the podcast by clicking >Here<
- [My PhD in Comics, 2025 edition](https://cepr-inserm.fr/2025/05/15/elementor-6089/): From the ocean depths to the laboratory bench, deep sea bacteria to combat respiratory diseases.   Congratulations to Alexis DAVID for taking part in the third edition of ‘My PhD in Comics’.He collaborated with Pellichi, PhD in biology and mangaka, to create a comic strip illustrating his thesis. For the PhD students, this experience is an opportunity to learn about scientific outreach, because putting their work into pictures requires discussion and follow-up with the illustrator. He will be calling on their ability to explain their thesis subject in terms that are suitable for any audience. The aim is to show
- [FAIR Project Reaches Key Milestone with Launch of Phase I Clinical Trial](https://cepr-inserm.fr/2025/04/29/fair-project-reaches-key-milestone-with-launch-of-phase-i-clinical-trial/): The EU-funded FAIR project has reached a major milestone with the start of a Phase I clinical trial for FLAMOD, an innovative therapy targeting respiratory infections. The trial is being conducted at the Clinical Investigation Centre of the Academic Hospital of Tours, France, led by Prof. Antoine Guillon. Unlike traditional antibiotics, FLAMOD boosts the body’s own immune response and is designed to work alongside antibiotics to improve their effectiveness. Derived from flagellin—a natural bacterial component—FLAMOD is delivered via aerosol using an Aerogen mesh nebulizer to directly stimulate lung immunity without triggering widespread inflammation. “This is a novel approach that directly
- [We are very proud and pleased to have received funding from the ANRS-MIE as part of the PEPR 2024 project.](https://cepr-inserm.fr/2025/04/28/we-are-very-proud-and-pleased-to-have-received-funding-from-the-anrs-mie-as-part-of-the-pepr-2024-project/): The PEPR 2024 project is coordinated by Mathieu Epardaud (ISP – INRAe/University of Tours) and Thomas Sécher (CEPR – Team 3 – Inserm/University of Tours). 🔬- InHEALation – aims to develop an innovative prophylactic and therapeutic inhaled platform against respiratory viruses.
- [Well Done Thomas Baranek for securing a grant from Ligue contre le Cancer to support his work on the antitumoral activities of iNKT cell subsets](https://cepr-inserm.fr/2025/04/04/elementor-5910/): Thomas obtained a one-year grant from LCC37 to support his study
- [Congratulations to Noemie Alphonse for obtaining both EMBO and MSCA Postdoctoral Fellowships](https://cepr-inserm.fr/2025/03/27/congratulations-to-noemie-alphonse-for-obtaining-both-embo-and-msca-postdoctoral-fellowships/): Noemie Alphonse obtained EMBO and MSCA (Marie Skłodowska-Curie Actions) Postdoctoral Fellowships.
- [From Coffee to Discoveries: CEPR’s Morning Meetup](https://cepr-inserm.fr/2025/02/28/from-coffee-to-discoveries-ceprs-morning-meetup/): Brewing Ideas Over Breakfast: The CEPR Team Gathers for a Moment of Exchange
- [CEPR's SAChA project: A new lease of life for influenza treatment](https://cepr-inserm.fr/2025/02/28/ceprs-sacha-project-a-new-lease-of-life-for-influenza-treatment/): Anti-influenza therapeutic solutions, whether preventive or curative, are sub-optimal. Antivirals currently on the market have a very short efficacy window, which calls into question their real-life effectiveness. The innovative SAChA project provides proven curative efficacy several days after the initial influenza infection. This natural metabolite of interest simultaneously targets viral multiplication and the excessive inflammatory response. It is this dual effect that confers a crucial advantage in the treatment of serious complications of influenza, surpassing the capabilities of current treatments.   Watch the video presentation of the SAChA project here :
- [Launch of the NEBUFLAG study at Tours University Hospital](https://cepr-inserm.fr/2025/01/30/launch-of-the-nebuflag-study-at-tours-university-hospital/): Today, January 28, the Nebuflag study is being launched at the CHRU in Tours, France. This is the 3rd stage of a larger research project, led by a consortium of European researchers*, and financed by European funds, notably Horizon 2020. This study is the 1st to be carried out on healthy, spontaneously breathing volunteers. One of the aims is to test the human response to the treatment currently being developed, called FLAMOD. This is a flagellin aerosol therapy for the treatment of drug-resistant bacterial pneumonia.Pneumonia is a type of respiratory tract infection that causes inflammation of the pulmonary alveoli –
- [Announcement symposium “Epithelial cells: The conductors of inflammation” on March 15, 2025](https://cepr-inserm.fr/2025/01/15/elementor-5540/): Announcement symposium “Epithelial cells: the conductors of inflammation” 📅 Date: March 15, 2025; https://gremi.asso.fr/PGE2uk/uk_registration.htm Preliminary Program Printable Poster (A4, pdf) of the One-Day GREMI meeting Abstract deadline: January 20th, 2025 Conference site: Pasteur Institute (Paris) – Duclaux Lecture Theater (access: 205 rue de Vaugirard, Paris 15ème). At the entrance of the Pasteur Institute, your ID card will be requested.Registration payment includes lunch. Abstracts, posters (1m height x 0.70m large) and slides will be in English. Oral communications will preferably be in English or eventually in French. The poster size will be specified later. Suggested Hotel (Pasteur Institute rate, will be updated).
- [All the Lab Wishes Anita a Well-Deserved Retirement !](https://cepr-inserm.fr/2025/01/13/all-the-lab-wishes-anita-a-well-deserved-retirement/): After many years of dedication, Anita will now enjoy a well-deserved retirement. We wish her all the best for this new chapter in her life !
- [Congratulation to Camille David for his Thesis defense !](https://cepr-inserm.fr/2024/12/11/congratulation-to-camille-david-for-his-thesis-defense/): Congratulations to Camille David for the successful defense of his thesis, « The influenza virus induces distinct alterations in alveolar macrophages in humans and mice: a comparative translational analysis«.
- [Congratulations to Thomas Secher on obtaining his HDR](https://cepr-inserm.fr/2024/12/09/congratulations-to-thomas-secher-on-obtaining-his-hdr-habilitation-to-direct-research/): Congratulations to Thomas, who brilliantly obtained his habilitation to direct research ! This is a remarkable accomplishment that reflects his  dedication and expertise in the field of therapeutic antibodies for the treatment of respiratory diseases. Wishing him every success in his academic journey !
- [Congratulation to Emilie Barsac for her thesis defense](https://cepr-inserm.fr/2024/11/28/congratulation-to-emilie-barsac-for-her-thesis-defense/): Congratulations to Emilie Barsarc for the successful defense of her thesis, “Study of MAIT cell impact during pneumococcal-mediated pneumonia“.   Her work allows a better characterization of transactivation mechanisms linked to the protective functions of MAIT cells, offering valuable insights into immune responses against pneumococcal infections. 
- [ERS Virtual School : Nebulisation of drugs for treatment of respiratory infections and disease - February 25, 2025](https://cepr-inserm.fr/2024/11/27/ers-virtual-school-nebulisation-of-drugs-for-treatment-of-respiratory-infections-and-disease-february-25-2025/): Join the ERS Virtual School of Nebulisation of Drugs for Treatment of Respiratory Infections and Disease in collaboration with the Horizon 2020 FAIR project in which CEPR teams have been involved. Click here to get more informations, program and register link  Date : February 25, 2025  
- [OneDay GREMI Meeting : EPITHELIAL CELLS: CONDUCTORSOF THE INFLAMMATORY ORCHESTRA - March 14, 2025](https://cepr-inserm.fr/2024/11/14/oneday-gremi-meeting-epithelial-cells-conductorsof-the-inflammatory-orchestra-march-14-2025/): The Group for Research and Studies on Mediator of Inflammation is organizing conferences on March 14, 2025 Registration Link
- [Characterization of anatomical variations of the nasal cavity in a subset of European patients and their impact on intranasal drug delivery](https://cepr-inserm.fr/2024/11/14/characterization-of-anatomical-variations-of-the-nasal-cavity-in-a-subset-of-european-patients-and-their-impact-on-intranasal-drug-delivery/): Mike Pasteur, Guillaume Arsouze, Guy Ilango, Déborah Le Pennec ,Dimitri Kulker, Anaïs Heyraud, Jean-Philippe Cottier, Charles Aussedat, Nathalie Heuzé-Vourc’h, Virginie Hervé, Sandrine Le Guellec Anatomical 3D-printed nasal casts are valuable models to investigate intranasal drug deposition, providing preclinical data that cannot be obtained in animal models. However, these models are limited since they are often derived from a single patient or represent a mean of several groups.  The present study aimed to better characterize the anatomical differences of the nasal cavity in a European sub-population and to assess the potential impact of anatomical variations on intranasal deposition by medical devices.
- [Join The free Webinar on Seasonal respiratory infections - November 22, 2024](https://cepr-inserm.fr/2024/11/14/22th-of-november-join-the-free-webinar-on-seasonal-respiratory-infections/): Join this free webinar co-organized by Mustapha Si-Tahar and colleagues from the french-speaking respiratory health research networks : RSRQ (Quebec/Canada), RESPIREnT (France) et BeRS (Belgium). Participation at the webinar is free, but registration is compulsory via the following link : https://splf.fr/activites-scientifiques-conjointes-rsrq-respirent-bers/
- [The CEPR is decked out in pink in support of #OctobreRose](https://cepr-inserm.fr/2024/10/17/the-cepr-is-decked-out-in-pink-in-support-of-octobrerose/): “Pink October” celebrates its 31st anniversary in 2024. The event, symbolized by the pink ribbon, focuses on organized screening, in conjunction with the French National Cancer Institute. The slogan of the information and awareness campaign running throughout October is: “Stronger together! The aim of Pink October is to raise awareness and encourage breast cancer screening, with a view to reducing the number of deaths caused by this cancer.  
- [CEPR's SAChA project honored by Inserm's hebdo santé en BD!](https://cepr-inserm.fr/2024/10/17/ceprs-sacha-project-honored-by-inserms-hebdo-sante-en-bd/): Inserm’s “Boîte à gants”, a new way of discovering science and medical research, is spotlighting the SAChA project by Mustapha Si-Tahar, Antoine Guillon and Adeline Cezard (team 1) in a comic strip. Instagram La Boîte à Gants
- [Discover the CEPR with the Science Festival 2024!](https://cepr-inserm.fr/2024/10/17/discover-the-cepr-with-the-science-festival-2024/): The CEPR was excited to take part in the Science Festival, inviting the public to discover the fascinating world of respiratory diseases. Through an open house event and a interactive stand at the Science Village, visitors of all ages had the chance to learn, explore, and engage with experts in a fun and interactive way! Précédent Suivant
- [IFN-gamma primes bone marrow neutrophils to acquire regulatory functions in severe viral respiratory infections](https://cepr-inserm.fr/2024/10/15/ifn-gamma-primes-bone-marrow-neutrophils-to-acquire-regulatory-functions-in-severe-viral-respiratory-infections/)
- [A Grand Prize in France2030 iPhD national competition for CEPR!](https://cepr-inserm.fr/2024/09/27/elementor-5079/): CEPR Team 1’s SAChA project wins Grand Prize in France2030 iPhD national competition! Adeline Cezard, former PhD student and current young postdoctoral researcher with Team 1 CEPR, has won one of the Grand Prizes in the France2030 iPhD national competition! 🏆 This distinction highlights her contribution to the SAChA project, an innovative program dedicated to the development of antiviral therapies, co-funded by C-VaLo and the CATRIEM consortium.
- [Learn more about Advances in Respiratory Pathologies](https://cepr-inserm.fr/2024/09/05/learn-more-about-advances-in-respiratory-pathologies/): For the “Fête de la Science”, come and visit our stand in the “Village des Sciences”. For the Fête de la Science on October 12 and 13, 2024, we invite you to visit our stand at the “Village des Sciences” 2024. Come and explore the research carried out by our four teams, who are joining forces to better understand the cellular and molecular mechanisms of inflammatory and infectious phenomena within our lungs, in order to propose new therapeutic strategies. Don’t miss this unique opportunity to delve into the heart of scientific research and see how our Center strives to push
- [Researcher for an hour : an animated tour of Our laboratory.](https://cepr-inserm.fr/2024/09/05/researcher-for-an-hour-an-animated-tour-of-our-laboratory/): Come and discover the world of research and learn more about respiratory diseases! In the age of multidisciplinary knowledge, the concept of “Ocean of Knowledge” takes on its full meaning in medical research. Within this universe, the 4 teams at the Research Center for Respiratory Diseases are experimenting, analyzing and working in synergy to better understand the cellular and molecular mechanisms involved in these inflammatory and infectious phenomena, in order to navigate towards new therapeutic frontiers. As part of the Fête de la Science, the Research Center for Respiratory Diseases will be opening its doors to you on October 8,
- [CEPR's team 4 obtained a 4-year grant from the ANR (AAPG2024) to evaluate the mechanisms that control Innate T cells (coordinator: C. Paget).](https://cepr-inserm.fr/2024/07/30/ceprs-team-4-obtained-a-4-year-grant-from-the-anr-to-evaluate-the-mechanisms-that-control-innate-t-cells/)
- [4-year ANR funding obtained (PROJECT COORDINATION: M. Si-Tahar): Development of Succinate-based analogues and formulations against SARS-CoV-2 and influenza viruses-induced respiratory infections – (SuccesS)](https://cepr-inserm.fr/2024/07/02/obtention-dun-financement-anr-de-4-ans-coordonnateur-m-si-taharintitule-developpement-danalogues-et-de-formulations-a-base-de-succinate-contre-les-infections-respiratoires-induites-par-le-s/): The emergence of pandemic respiratory viruses is a major concern. Those viruses include coronaviruses such as SARS-CoV-2 and influenza A viruses (IAV). There are currently no efficient drugs against coronaviruses and the efficacy of anti-IAV drugs is disputed. Vaccination should constitute the most preventive strategy. However, the intrinsic antigenic drift of IAV impairs vaccine protection. Besides, previous coronaviruses crises showed that poorly neutralizing antibodies developed after vaccination may enhance subsequent infection. Current vaccine hesitancy also remains a barrier to full population inoculation against SARS-CoV-2. Our ANR project is thus aimed to develop an innovative metabolic therapy against those two viruses,
- [Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein"](https://cepr-inserm.fr/2024/07/02/host-succinate-inhibits-influenza-virus-infection-through-succinylation-and-nuclear-retention-of-the-viral-nucleoprotein-et-le-communique-de-presse-de-linserm/): Antoine Guillon, Deborah Brea-Diakite, Adeline Cezard, Alan Wacquiez, Thomas Baranek, Jérôme Bourgeais, Frédéric Picou, Virginie Vasseur, Léa Meyer, Christophe Chevalier, Adrien Auvet, José M Carballido, Lydie Nadal Desbarats, Florent Dingli, Andrei Turtoi, Audrey Le Gouellec, Florence Fauvelle, Amélie Donchet, Thibaut Crépin, Pieter S Hiemstra, Christophe Paget, Damarys Loew, Olivier Herault, Mustapha Si-Tahar, […] source : https://febs.onlinelibrary.wiley.com/doi/full/10.1111/febs.15229
- [Human proteinase 3 resistance to inhibition extends to alpha-2 macroglobulin.](https://cepr-inserm.fr/2024/07/02/human-proteinase-3-resistance-to-inhibition-extends-to-alpha-2-macroglobulin/): N’Guessan K, Grzywa R, Seren S, Gabant G, Juliano MA, Moniatte M, van Dorsselaer A, Bieth JG, Kellenberger C, Gauthier F, Wysocka M, Lesner A, Sienczyk M, Cadene M, Korkmaz B. FEBS J. 2020 Jan 29.  source : https://febs.onlinelibrary.wiley.com/doi/full/10.1111/febs.15229
- [Interleukin- 7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response.](https://cepr-inserm.fr/2024/02/22/vers-un-avenir-respiratoire-plus-sain/): Hassane M, Jouan Y, Creusat F, Soulard D, Boisseau C, Gonzalez L, Patin EC, Heuzé-Vourc’h N, Sirard JC, Faveeuw C, Trottein F, Si-Tahar M, Baranek T, Paget C. Mucosal Immunol. 2020 Jan;13(1):128-139.      Source : Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response – ScienceDirect
- [Inhalation of Immuno-Therapeutics/-Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right Place!](https://cepr-inserm.fr/2024/01/10/devoiler-les-secrets-des-proteases-pulmonaires-une-caracterisation-moleculaire-approfondie/): Inhalation of Immuno-Therapeutics/-Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right   Sécher T, Mayor A, Heuzé-Vourc’h N. Front Immunol. 2019 Nov 29;10:2760.  source : https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02760/full
- [CEPR's team 4 obtained a 4-year grant from the ANR (AAPG2023) to assess the role and functions of MAIT cells during influenza infection (coordinator: Y. Jouan).](https://cepr-inserm.fr/2023/07/30/ceprs-team-4-obtained-a-4-year-grant-from-the-anr-aapg2023-to-assess-the-role-and-functions-of-mait-cells-during-influenza-infection-coordinator-y-jouan/)

## Pages

- [teams-alumni-4](https://cepr-inserm.fr/teams-alumni-4/): Alumni team 1 team 2 team 3 team 4 Team 4 Researchers & Postdoctoral Fellows Ph.D. Students Emilie Barsac (2020-2024) Florent Creusat (2016-2019) Youenn Jouan (2016-2019) Engineers Léa Carvalho (2021-2023)
- [teams-alumni-3](https://cepr-inserm.fr/teams-alumni-3/): Alumni team 1 team 2 team 3 team 4 Team 3 Researchers & Postdoctoral Fellows Mélanie CORTEZ (2020-2021) Laurent VECELLIO (2012 -2020) Renaud RESPAUD (2012 – 2019) Jacques CHANDENIER (2012 – 2019) Emilie DALLONEAU (2013 – 2020) Patrice DIOT (< 2012 – 2020) Nabile BOUKHETTALA (2012 – 2016) Denis MARCHAND (2012 – 2016) Alain LEPAPE (<2012 -2015) Said LARIBI (2014-2020) Mirvate FRANCIS (2012-2013) Ph.D. Students Aubin PITIOT (2020-2023) Justina CREPPY (2019-2023) Coralie Mergault (2018-2022) Alexie MAYOR (2017-2020) Elsa MONTAGUTELLI (2016-2020) David CHAUVIN (2015-2018) Melia MAGNEN (2014-2017) Francois REMIGNAC (2013-2017) Laurent GUILLEMINAULT (<2012) Thomas KRYZA (<2012) Engineers Aurélie DOMENE (2017-2019)
- [teams-alumni-2](https://cepr-inserm.fr/teams-alumni-2/): Alumni team 1 team 2 team 3 team 4 Team 2 Researchers & Postdoctoral Fellows Étienne AUVERT (2024) Roxane DOMAIN (2023-2024) Mounia TAHRI JOUTEY (2023-2024) Rania ALLOUCHE (2022-2023) Seda SEREN (2019-2020) Pascale REVERDIAU (2012-2023) Yves COURTY (2012-2020) Francis GAUTHIER (2012-2018) Thierry MOREAU (2012-2017) Marie-Louise ZANI (2012-2017) Ph.D. Students Benjamin VICTOIR (2021-2024) Étienne AUVERT (2020-2023) Camille BLOUET (2020-2023) Roxane DOMAIN (2020-2023) Paul BIGOT (2019-2022) Woodys LENGA MA BONDA (2017-2021) Koffi N’GUESSAN (2016-2020) Seda SEREN (2016-2019) Mylene WARTENBERG (2015-2021) Melia MAGNEN (2014-2017) Carla GUARINO (2013-2016) Anne-Sophie LAMORT (2012-2016) Pierre-Marie ANDRAULT (2012-2015) Mariana KASABOVA (2010-2013) Juliette SAGE (2009-2012) Anabelle TANGA (2009-2012)
- [teams-alumni](https://cepr-inserm.fr/teams-alumni/): Alumni team 1 team 2 team 3 team 4 Team 1 Postdoctoral Fellows Ana Raquel CONDUTO DIAS MAIA (2021-2023) Alan WACQUIEZ (2017-2020) Eric MORELLO (2013-2017) Ph.D. Students Florent CREUSAT (2016-2019) Alexandre VALAYER (2014-2020)   Engineers Badréddine Bounab (2024-2024)
- [team-2 - Dupliquer - [#1925]](https://cepr-inserm.fr/__trashed-3/): Team 2 Proteolytic enzymes and their pharmacological targeting in lung diseases Team leader : Brice KORKMAZ Team 2 is a basic research team oriented to a multidisciplinary and translational research investigating proteolytic mechanisms associated with two chronic pulmonary diseases (chronic obstructive pulmonary disease (COPD) and fibrosis) and lung cancer.  Our group also investigates interventional strategies for targeting lung proteases in the inflammatory microenvironment. For that we develop on the one hand innovative methods of synthesis to prepare new small chemical (heterocyclic) inhibitors and, in an other hand we design and produce original antibody-drug conjugates (ADCs, a targeted therapy, allowing selective
- [publications-4](https://cepr-inserm.fr/publications-4/): Publications​ team 1 team 2 team 3 team 4 Team 4 2025 Aurelie Drouin , Laurine Durand , Clara Esnault , Pauline Gaboriaud , Valérie Leblond , Shawk Karim , Morgane Fouché , Christine Dhommée , Christine B Baltus , Fanny Boursin , Nicolas Aubrey , Roland Houben , David Schrama , Serge Guyétant , Audrey Desgranges , Marie Claude Viaud-Massuard , Valérie Gouilleux-Gruart , Mahtab Samimi , Thibault Kervarrec , Antoine Touzé. Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers. J Immunother Cancer. 2025 Mar 13;13(3):e010897. doi: 10.1136/jitc-2024-010897. Maia AR, Gonzalez L, Bounab B, Grassi L, Mousset C, Fromont-Hankard G, Cezard A, Hiemstra P, Baranek T, Paget C, Crabbé A, Si-Tahar M. Intranasal exposure to commensal bacterium Rothia mucilaginosa protects against influenza A virus infection. Antiviral Res. 2025 Feb:234:106076. doi: 10.1016/j.antiviral.2025.106076 2024   Mike
- [publications-3](https://cepr-inserm.fr/publications-3/): Publications​ team 1 team 2 team 3 team 4 Team 3 2026 Kaur B, Sécher T, Heuzé-Vourc’h N. Excipients in orally inhaled protein formulations: current examples, challenges, and future directions. Drug Discovery Today. 2026 doi: 10.1016/j.drudis.2026.104642 Bosc L, Sécher T, Ball G, Le Pennec D, Tribout M, Ba M, Bai Y, Ouerdane L, Arnoux P, Denis Y, Lei X, Bordi C, Heuzé-Vourc’h N, Häussler S, Gomez NO, Voulhoux R. Pseudopaline-mediated zinc uptake by Pseudomonas aeruginosa drives clinically relevant phenotypes and infection outcomes. Infect Immun. 2026 Feb 10;94(2):e0045325. doi: 10.1128/iai.00453-25 2025 Baldry M, Caballero I, Ruuls L, Cayet D, Zeroual Y, Costa C,
- [publications-2](https://cepr-inserm.fr/publications-2/): Publications​ team 1 team 2 team 3 team 4 Team 2 2025 Diesler R, Gallay L, Uzunhan Y, Borie R, Reynaud-Gaubert M, Valentin V, Ahmad K, Lazor R, Wemeau L, Traclet J, Rigaud P, Marchand-Adam S, Israël-Biet D, Hirschi S, Bonniaud P, Froidure A, Montani D, Naccache JM, Romain-Scelle N, Cottin V; OrphaLung Network. Risk of hospitalisation and mortality among patients with interstitial lung disease and COVID-19: A French multicentre prospective cohort. Pulmonology. 2025 Dec 31;31(1):2598693 doi: 10.1080/25310429.2025.2598693 Nishimwe D, Guillon G, Mallavialle A, Martin C, Huvelle S, Alcaraz LB, Romero A, Garapon C, Garambois V, Mansouri H, Boissière-Michot F,
- [sitemap](https://cepr-inserm.fr/sitemap/): Sitemap
- [legal-notice](https://cepr-inserm.fr/legal-notice/): Legal notice Website PublisherName: Research center for respiratory diseases – Centre d’étude des pathologies respiratoires (CEPR)Email: secretariat.cepr@univ-tours.fr Website Creation The website was created by: Lalé Studio Créatif Phone:0651102703 Email: contact@lalestudiocreatif.fr Website Hosting The website is hosted by: Hostinger Address: 61 Lordou Vironos Street, 6023 Larnaca, Cyprus Phone: +1 000-000-0000 Email: support@hostinger.com Intellectual PropertyThe content of the website https://cepr-inserm.fr/ (texts, images, videos, logos, etc.) is protected by copyright. Any reproduction, distribution, modification, or publication of these elements is prohibited without the express authorization of CEPR.Some of the images are from www.freepik.com Personal Data ProtectionUser rights: You have the right to access,
- [old-Infos](https://cepr-inserm.fr/old-infos-2/): Nos équipes Équipe 1 A short description of your service. Lorem ipsm dolor amet, consec tetur adipis cing elit, sed do eiusmod tempor incid idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer citation ullamco la enim lorem isae ni. Voir plus Équipe 2 A short description of your service. Lorem ipsm dolor amet, consec tetur adipis cing elit, sed do eiusmod tempor incid idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer citation ullamco la enim lorem isae ni. Voir plus Équipe 3 A short description of
- [more-information](https://cepr-inserm.fr/more-information/): More information Administrative management Catherine DOUTEAU 02.47.36.60.49 Anne-Sophie VENET02.47.36.60.79 E-mail : secretariat.cepr@univ-tours.fr Where to find us Centre d’Etude des Pathologies Respiratoires (CEPR) INSERM U1100 Faculté de MédecineUniversité de Tours 10, boulevard Tonnellé37032 Tours cedex, France Prepare your visit By BUS From Tours train station, you can take Tram line A and then Bus line 4, and get off at the Bretonneau station stop (~30min).  You can also take Bus line 5 (from both Tours and Saint-Pierre-Des-Corps Train station) and get off at Arago. This stop is a 5-min walk from our laboratory.  https://www.filbleu.fr/ By train From Paris, you can take high-speed and
- [Home](https://cepr-inserm.fr/): Centre d’Etude des Pathologies Respiratoires Research Center for Respiratory Diseases About us Linkedin Mustapha Si-Tahar (Head of CEPR) The Research Center for Respiratory Diseases (CEPR) is an academic laboratory comprising 4 teams situated in Tours , France, within the shared campus of the Faculty of Medicine and the Bretonneau University Hospital (CHU). It was established in 2012 by the INSERM (National Institute of Health and Medical Research) and the University of Tours. Since then, CEPR is directed by Dr. Mustapha Si-Tahar (Inserm Research Director (DR1) ). Since 2024, he has also been supported by Dr. Fabrice Gouilleux (CNRS Research Director
- [team-4-members](https://cepr-inserm.fr/team-4-members/): Team 4 Members Team leaders Christophe PAGET Research Professor (DR2, INSERM) christophe.paget@inserm.fr Thomas BARANEK Associate Professor baranek@univ-tours.fr Researchers Valérie GOUILLEUX-GRUART Associate Professor valerie.gouilleux@univ-tours.fr Youenn JOUAN Clinician youenn.jouan@univ-tours.fr Alexandra AUDEMARD-VERGER Full Professor – Clinician alexandra.audemardverger@univ-tours.fr Hervé WATIER Full Professor – Clinician herve.watier@univ-tours.fr Salomé CARCY Postdoctoral fellow salome.carcy@univ-tours.fr Benjamin THOREAU AHU – Clinician benjamin.thoreau@univ-tours.fr Technical staff Loïc GONZALEZ Engineer Assistant loic.gonzalez@univ-tours.fr Matthieu BENARD Lab technician matthieu.benard@inserm.fr Guy ILANGO Bioinformatician guy.ilango@univ-tours.fr PhD Students Pierre BOULARD pierre.boulard@univ-tours.fr Yanis RAMDANI yanis.ramdani@univ-tours.fr Antoine HANKARD antoine.hankard@etu.univ-tours.fr Fabian RICHTER fabian.richter@etu.univ-tours.fr Louna PILI louna.pili@univ-tours.fr Carla RIBEIRO carla.ribeiro@etu.univ-tours.fr
- [team-3-members](https://cepr-inserm.fr/team-3-members/): Team 3 Members Team leaders Nathalie HEUZE-VOURC’H Research Professor (DR2, INSERM) nathalie.vourch@univ-tours.fr Laurent PLANTIER Associate Professor laurent.plantier@univ-tours.fr Researchers Thomas SECHER Research Scientist (CRNC-INSERM) thomas.secher@univ-tours.fr Charles AUSSEDAT Clinician charles.aussedat@univ-tours.fr François BARBIER Full Professor – Clinician francois.barbier@chr-orleans.fr Stephan EHRMANN Full Professor – Clinician stephan.ehrmann@univ-tours.fr Marion FERREIRA Clinician marion-ferreira@chu-tours.fr Virginie HERVE Associate Professor virginie.herve-grepinet@univ-tours.fr Sylvain MORINIERE Full Professor – Clinician sylvain.moriniere@univ-tours.fr Damien SIZARET Clinician d.sizaret@chu-tours.fr Rodrigo GUABIRABA Research scientist (IR-INSERM) guabirababrito@univ-tours.fr  Bhupinder KAUR Postdoctoral researcher bhupinder.kaur@univ-tours.fr Noémie FOURNIER Postdoctoral researcher noemie.fournier@univ-tours.fr Sandra KHAU Postdoctoral researcher sandra.khau@univ-tours.fr Mike PASTEUR Postdoctoral researcher mike.pasteur@univ-tours.fr Technical staff Marlène BEAUJEON Engineer Assistant marlene.beaujeon@univ-tours.fr Maria CABRERA Lab technician maria.cabrera@univ-tours.fr
- [team-4](https://cepr-inserm.fr/team-4/): Team 4 Biology of Innate T cells & Lung immunity Team leader : Christophe PAGET The “Biology of Innate T cells & Lung immunity” Lab conducts fundamental researches in the field of innate T (Tinn) cell immunobiology with a peculiar focus on lung immunity including infection and autoimmunity. Our team is organised around three complementary and interconnected axes. Our expertise includes advance knowledge in mouse and human immunology including innate T cell and Fc receptor biology, and the understanding of lung inflammation from autoimmune and infectious origins. These are valued by applying a translational research approach combining relevant experimental models
- [team-3](https://cepr-inserm.fr/team-3/): Team 3 PHARMACOLOGY OF INHALED PHARMACEUTICALS Team leader : Nathalie HEUZE-VOURC’H Scientific goals Communicateand disseminate the scientific knowledge on respiratory diseases and inhalation Accelerate the development of inhaled medicines/products and innovative devices Support the industrial actors for the development of new inhaled pharmaceuticals/inhalation technologies Foster the transfer of inhaled pharmaceuticals/inhalation technologies into the clinics Participate in the regulatory assessment and guideline establishment for the use of inhalation medicines/products Extend the use of inhalation to biotherapeutics (RNA, vaccines, therapeutic, antibodies, …) and innovative pharmaceuticals Research areas Study pharmacokinetics and pharmacodynamics of inhaled pharmaceuticalsDevelop inhaled formulations to improve drug stability/ efficacy Characterize
- [team-2-members](https://cepr-inserm.fr/team-2-members/): Team 2 Members Team leaders Brice KORKMAZ Research Scientist(CRNC-INSERM) brice.korkmaz@inserm.fr Gilles LALMANACH Full Professor gilles.lalmanach@univ-tours.fr Researchers Thibault CHAZEIRAT Postdoctoral researcher thibault.chazeirat@univ-tours.fr Cécile CROIX Research engineer cecile.croix@univ-tours.fr Sandrine DALLET-CHOISY Associate Professor sandrine.dallet@univ-tours.fr Alexis DAVID Temporary research and teaching assistant alexis.david@univ-tours.fr Caroline DENEVAULT Associate Professor caroline.denevault@univ-tours.fr Sophie IOCHMANN Associate Professor sophie.iochmann@univ-tours.fr Nicolas JOUBERT Full Professor nicolas.joubert@univ-tours.fr Marion LAVERGNE Associate Professor marion.lavergne@univ-tours.fr Fabien LECAILLE Full Professor fabien.lecaille@univ-tours.fr Sylvain MARCHAND-ADAM Full Professor – Clinician s.marchandadam@univ-tours.fr Agnès PETIT Associate Professor agnes.petit@univ-tours.fr Gildas PRIE Associate Professor gildas.prie@univ-tours.fr Ahlame SAIDI Research engineer ahlame.saidi@univ-tours.fr Pierre SIEROCKI Associate Professor pierre.sierocki@univ-tours.fr Florian VEILLARD Associate Professor florian.veillard@univ-tours.fr Marie-Claude VIAUD-MASSUARD Full Professor
- [team-2](https://cepr-inserm.fr/team-2/): Team 2 Proteolytic enzymes and their pharmacological targeting in lung diseases Team leader : Brice KORKMAZ Team 2 is a basic research team oriented to a multidisciplinary and translational research investigating proteolytic mechanisms associated with two chronic pulmonary diseases (chronic obstructive pulmonary disease (COPD) and fibrosis) and lung cancer.  Our group also investigates interventional strategies for targeting lung proteases in the inflammatory microenvironment. For that we develop on the one hand innovative methods of synthesis to prepare new small chemical (heterocyclic) inhibitors and, in an other hand we design and produce original antibody-drug conjugates (ADCs, a targeted therapy, allowing selective
- [old-teams-alumni](https://cepr-inserm.fr/old-teams-alumni/): Teams – ALUMNI Alumni Team 1 Postdoctoral Fellows   Ph.D. Students   Engineers Team 2 Researchers & Postdoctoral Fellows Rania ALLOUCHE (2022-2023) Seda SEREN (2016-2020) Pascale REVERDIAU (2012-2023) Yves COURTY (2012-2020) Francis GAUTHIER (2012-2018) Thierry MOREAU (2012-2017) Marie-Louise ZANI (2012-2017)   Ph.D. Students Paul BIGOT (2019-2022) Woodys LENGA MA BONDA (2017-2021) Koffi N’GUESSAN (2016-2020) Mylene WARTENBERG (2015-2021) Melia MAGNEN (2014-2017) Carla GUARINO (2013-2016) Anne-Sophie LAMORT (2012-2016) Pierre-Marie ANDRAULT (2012-2015) Mariana KASABOVA (2010-2013 Juliette SAGE (2009-2012) Marion LAVERGNE (2009-2012) Anabelle TANGA (2009-2012) Team 3 Researchers & Postdoctoral Fellows Mélanie CORTEZ (2020-2021) Laurent VECELLIO (2012 -2020) Renaud RESPAUD (2012 – 2019) Jacques
- [publications-1](https://cepr-inserm.fr/publications-1/): Publications​ team 1 team 2 team 3 team 4 Team 1 2025 Ana Raquel Maia, Loïc Gonzalez, Badreddine Bounab, Lucia Grassi, Coralie Mousset, Gaëlle Fromont-Hankard, Adeline Cezard, Pieter Hiemstra, Thomas Baranek, Christophe Paget, Aurélie Crabbé, Mustapha Si-Tahar. Intranasal exposure to commensal bacterium Rothia mucilaginosa protects against influenza A virus infection. Antiviral Research,Volume 234,2025,106076,ISSN 0166-3542. https://doi.org/10.1016j.antiviral.2025.106076.   2024 David C, Verney C, Si-Tahar M, Guillon A. The deadly dance of alveolar macrophages and influenza virus. Eur Respir Rev. 2024 Oct 30;33(174):240132. doi: 10.1183/16000617.0132-2024. PMID: 39477353; PMCID: PMC11522969. David, C.; Brea, D.; Verney, C.; Cezard, A.; Vasseur, V.; Briard, B.; Khau, S.; Barsac,
- [past-theses](https://cepr-inserm.fr/past-theses/): Past theses 2020-2025 – Mike PASTEUR – 2025Biomimetic model of human nasal cavity for drug developmentThesis supervisors : Virginie Hervé & Sandrine Le GuellecThesis defense : 19/12/2025 – Sandra KHAU– 2025 Study of inflammasome regulation during bacterial and fungal superinfection in cystic fibrosis.Thesis supervisors : Benoît Briard & Mustapha Si-TaharThesis defense : 18/12/2025 – Alexis DAVID – 2025Modulation of cysteine cathepsins activity by natural and synthetic polysaccharidesThesis supervisor : Fabien LecailleThesis defense : 09/12/2025 – Benjamin VICTOIR – 2024Design and synthesis of multifunctional agents targeting the hematopoietic niche in chemoresistant myeloid leukemia.Thesis supervisors : Gildas Prié & Cécile CroixThesis defense : 12/12/2024 –
- [theses-progress](https://cepr-inserm.fr/theses-progress/): Theses in progress – Chaymae El Jamali (2026): Investigating a new effector function of therapeutic antibodies in the lungsThesis supervisors: Thomas Sécher & Noémie Alphonse  – Louna Pili (2025): Mucosal-Associated Invariant T cells (MAIT) cells in severe viral pneumonia and Acute Respiratory Distress Syndrome.Thesis supervisors: Youenn Jouan & Christophe Paget – Carla Ribeiro (2024): Impact of thyroid hormones on iNKT lymphocyte differenciation and functions.Thesis supervisor: Thomas Baranek – Katia Montero-Diaz (2024) : Comprehensive analysis of immune responses to mRNA- based vaccines Thesis supervisors : Nathalie Heuzé-Vourc’h & Thomas Sécher – Valentine Cheron (2024) : Preclinical development of a new nanocrystallized inhaled
- [team-1](https://cepr-inserm.fr/team-1/): Team 1 PATHOPHYSIOLOGY OF LUNG INFECTIONS Team leader : Sandrine HENRI The ‘Pathophysiology of Lung Infections’ team conducts cross-disciplinary research in the field of respiratory infections.  The team’s strength lies in its membership which includes researchers, associate professors, clinicians, engineers, technicians, post-docs and PhD students with complementary expertise in immunology, microbiology, molecular and cell biology. We are engaged in developing fundamental research programs, pre-clinical and clinical studies. Our goal is to develop innovative immune-intervention and antimicrobial strategies.Specifically, we investigate the interplay of key molecular and cellular effectors in response to respiratory infections caused by viruses, bacteria, and fungi.Our goal is
- [old-home-2](https://cepr-inserm.fr/old-home-2/): Centre d’Etude des Pathologies Respiratoires Research Center For Respiratory Diseases About us About Us:The Research Center for Respiratory Diseases (CEPR) is an academic laboratory comprising 4 teams situated in Tours, France, within the shared campus of the Faculty of Medicine and the Bretonneau University Hospital (CHU). It was stablished in 2012 by the INSERM (National Institute of Health and Medical Research) and the University of Tours. Since then, CEPR is directed by Dr. Mustapha Si-Tahar (DR1 Inserm). Our Research Focus:With a total of approximately 85 members, CEPR focuses on elucidating the molecular and cellular mechanisms underlying inflammatory and infectious respiratory
- [news](https://cepr-inserm.fr/news/): News All Animation Event Funding Publication Thesis FAIR Project Reaches Key Milestone with Launch of Phase I Clinical Trial Event The EU-funded FAIR project has reached a major milestone with the start of a Phase I clinical trial for FLAMOD,… Read more We are very proud and pleased to have received funding from the ANRS-MIE as part of the PEPR 2024 project. Funding The PEPR 2024 project is coordinated by Mathieu Epardaud (ISP – INRAe/University of Tours) and Thomas Sécher (CEPR – Team… Read more Well Done Thomas Baranek for securing a grant from Ligue contre le Cancer to support
- [old-Infos](https://cepr-inserm.fr/old-infos/): Infos pratiques Mustapha SI-TAHAR Directeur Nathalie HEUZE-VOURC’H Directrice adjoint GESTION ADMINISTRATIVE Catherine DOUTEAU 02.47.36.60.49 Anne-Sophie VENET02.47.36.60.79  E-mail : secretariat.cepr@univ-tours.fr Où nous trouver ? Centre d’Etude des Pathologies Respiratoires (CEPR) INSERM U1100Faculté de Médecine, Université de Tours10, boulevard Tonnellé37032 Tours cedex Bâtiment 47C Bâtiment 47C Le bâtiment qui accueille le laboratoire Bâtiment M Bâtiment M xxx Bâtiment Vialle Bâtiment Vialle xxx Notre laboratoire est à l’arrière du bâtiment 47 (voir plan ci-dessous) au rez-de-chaussée. C’est un petit bâtiment blanc de deux étages qui donne sur la rue Victor Hugo (il existe une sortie de l’hôpital juste à côté). Préparer votre venue au laboratoire
- [team-1-members](https://cepr-inserm.fr/team-1-members/): Team 1 Members Team leaders Sandrine HENRI Team Leader sandrine.henri@univ-tours.fr Mustapha SI-TAHAR Deputy Team Leader mustapha.si-tahar@univ-tours.fr Technical staff Déborah DIAKITE UT IE deborah.brea@univ-tours.fr Delphine FOUQUENET UT AI delphine.fouquenet@univ-tours.fr Virgine VASSEUR INSERM IE virginie.vasseur@univ-tours.fr Researchers Sandrine HENRI INSERM DR2 sandrine.henri@univ-tours.fr Mustapha SI-TAHAR INSERM DR1 mustapha.si-tahar@univ-tours.fr Benoît BRIARD INSERM CRCN benoît.briard@univ-tours.fr Fabrice GOUILLEUX CNRS DR2 fabrice.gouilleux@univ-tours.fr Lecturer/Professor Elise BIQUAND UT MCF elise.biquand@univ-tours.fr Adélaïde CHESNAY PHU adelaide.chesnay@univ-tours.fr Pierre-François DEQUIN UT PU-PH pierre-francois-dequin@univ-tours.fr Guillaume DESOUBEAUX UT PU-PH guillaume.desoubeaux@univ-tours.fr Antoine GUILLON UT PU-PH antoine.guillon@univ-tours.fr Under contract Adeline CEZARD Post doc adeline.cezard@univ-tours.fr Quentin GUILBERT Assistant-engineer quentin.guilbert@univ-tours.fr Camille David Post doc camille.david@univ-tours.fr Maaike SUURING Post doc maaike.suuring@univ-tours.fr
- [old-Équipes](https://cepr-inserm.fr/old-teams/): équipes Équipe 1 L’ambition de l’équipe « Infection respiratoire et Immunité » est de développer une recherche transversale performante dans le domaine des infections respiratoires. Les atouts de cette équipe reposent sur les membres qui lui sont associés. Il s’agit d’expert en immunologie, en microbiologie, et en effecteurs moléculaires de la défense de l’hôte ainsi que de médecins-réanimateurs. L’équipe est donc à même de développer à la fois des programmes de recherche fondamentaux basés sur des approches moléculaires et mécanistiques, des expérimentations in vivo ainsi que sur des investigations pré-cliniques et cliniques. Voir plus Équipe 2 L’équipe est rattachée à


[comment]: # (Generated by Hostinger Tools Plugin)